MENU
+Compare
FATE
Stock ticker: NASDAQ
AS OF
Dec 12 closing price
Price
$1.15
Change
+$0.04 (+3.60%)
Capitalization
132.66M

FATE Fate Therapeutics Forecast, Technical & Fundamental Analysis

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States... Show more

Industry: #Biotechnology
FATE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for FATE with price predictions
Dec 11, 2025

FATE's RSI Oscillator recovers from oversold territory

The RSI Indicator for FATE moved out of oversold territory on November 18, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In of the 39 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 10, 2025. You may want to consider a long position or call options on FATE as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for FATE just turned positive on November 25, 2025. Looking at past instances where FATE's MACD turned positive, the stock continued to rise in of 59 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FATE advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 53 cases where FATE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The 10-day moving average for FATE crossed bearishly below the 50-day moving average on November 10, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for FATE entered a downward trend on November 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.567) is normal, around the industry mean (28.362). P/E Ratio (0.000) is within average values for comparable stocks, (51.986). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.836). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (19.084) is also within normal values, averaging (336.196).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. FATE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
FATE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

FATE is expected to report earnings to rise 1.56% to -27 cents per share on March 02

Fate Therapeutics FATE Stock Earnings Reports
Q4'25
Est.
$-0.27
Q3'25
Beat
by $0.03
Q2'25
Beat
by $0.05
Q1'25
Beat
by $0.07
Q4'24
Est.
$-0.44
The last earnings report on November 13 showed earnings per share of -27 cents, beating the estimate of -30 cents. With 1.41M shares outstanding, the current market capitalization sits at 132.66M.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12278 Scripps Summit Drive
Phone
+1 858 875-1800
Employees
220
Web
https://www.fatetherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GVYB22.00N/A
N/A
Golden Valley Bancshares, Inc.
RSHPF1.09N/A
N/A
Irish Residential Properties REIT PLC
RUBSF35.58N/A
N/A
RUBIS
NEXOY24.68-0.14
-0.56%
Nexon Co Ltd.
DRCR0.05N/A
-0.95%
Dear Cashmere Holding Co.

FATE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with RXRX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+1.83%
RXRX - FATE
51%
Loosely correlated
-3.98%
CRBU - FATE
50%
Loosely correlated
-2.11%
CRSP - FATE
48%
Loosely correlated
+0.87%
ALLO - FATE
47%
Loosely correlated
+4.73%
MGNX - FATE
46%
Loosely correlated
+0.71%
More